GlassScriptPhysician profile
Morris S Naus
NPI 1598751679
$193,161.98
in general payments reported to CMS, 2019-2025
47 companies · $32K in 2025
The $32K reported for 2025 was more than what 96% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $21K · 2020: $929 · 2021: $17K · 2022: $2,942 · 2023: $3,525 · 2024: $115K · 2025: $32K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $102K · Travel and Lodging: $27K · Food and Beverage: $14K · Honoraria: $4,527 · Consulting Fee: $3,773 · Education: $251.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $101,910.00 |
| Travel and Lodging | $26,619.55 |
| Food and Beverage | $14,039.59 |
| Honoraria | $4,526.50 |
| Consulting Fee | $3,772.50 |
| Education | $251.41 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Phathom Pharmaceuticals, INC. | $119,265.97 | 2024-2025 | Voquezna |
| Celltrion USA INC. | $23,014.73 | 2023-2025 | Zymfentra, Vegzelma, Yuflyma |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $21,848.97 | 2019-2025 | Xifaxan, Trulance |
| Takeda Pharmaceuticals U.S.A., INC. | $10,042.84 | 2019-2025 | Entyvio, Eohilia, Gattex |
| Abbvie INC. | $5,363.38 | 2019-2025 | |
| Otsuka America Pharmaceutical, INC. | $3,619.15 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $1,168.25 | 2021-2024 | Zeposia |
| Janssen Biotech, INC. | $1,043.61 | 2019-2025 | Tremfya, Stelara, Remicade |
| Pfizer INC. | $910.99 | 2019-2025 | |
| Celgene Corporation | $778.69 | 2021-2024 | Zeposia |
| Ardelyx, INC. | $739.17 | 2022-2025 | Ibsrela |
| Lilly USA, LLC | $415.65 | 2024-2025 | Omvoh |
| Genzyme Corporation | $398.34 | 2022-2025 | |
| Qol Medical, LLC | $363.31 | 2019-2025 | Sucraid, Sucraid |
| Merck Sharp & Dohme LLC | $349.64 | 2019-2024 | Dificid, Zinplava |
Show all 47 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ferring Pharmaceuticals INC. | $343.05 | 2019-2025 | Rebyota, Clenpiq |
| Cumberland Pharmaceuticals, INC. | $318.07 | 2019-2023 | Kristalose |
| Braintree Laboratories, INC. | $299.34 | 2019-2025 | Sutab, Suflave |
| Nestle Healthcare Nutrition INC. | $247.47 | 2021-2023 | |
| Intercept Pharmaceuticals, INC. | $238.07 | 2019-2024 | Ocaliva |
| Allergan, INC. | $235.00 | 2019-2020 | |
| Pharmacosmos Therapeutics INC. | $226.81 | 2023-2025 | Monoferric |
| Redhill Biopharma INC. | $218.75 | 2020-2022 | |
| Regeneron Healthcare Solutions, INC. | $172.19 | 2023-2025 | Dupixent |
| Janssen Scientific Affairs, LLC | $168.45 | 2022-2025 | Tremfya |
| Ironwood Pharmaceuticals, INC | $168.16 | 2019-2023 | Linzess |
| Medtronic, INC. | $162.69 | 2022-2023 | Interstim |
| Ucb, INC. | $125.98 | 2019-2021 | |
| Fresenius Kabi USA, LLC | $101.09 | 2023-2024 | Idacio |
| Aimmune Therapeutics, INC. | $97.59 | 2024-2025 | Zenpep, Vowst |
| Madrigal Pharmaceuticals | $88.21 | 2024-2025 | Rezdiffra, Resmetirom |
| Daiichi Sankyo INC. | $86.49 | 2019-2022 | |
| Romark Laboratories, Lc | $65.86 | 2019-2020 | |
| Vivus LLC | $56.27 | 2020-2025 | Pancreaze |
| Endo Pharmaceuticals INC. | $55.44 | 2020-2022 | |
| Axonics, INC. | $54.98 | 2023-2024 | Axonics |
| Gilead Sciences, INC. | $53.73 | 2019-2022 | |
| Shire North American Group INC | $45.47 | 2019 | |
| Evoke Pharma, INC. | $45.26 | 2021-2023 | Gimoti |
| Shionogi INC | $26.05 | 2019 | |
| Amgen INC. | $25.56 | 2022 | |
| Boston Scientific Corporation | $23.81 | 2025 | General - Polypectomy |
| Alnylam Pharmaceuticals INC. | $20.74 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $19.89 | 2023 | |
| Biocon Biologics INC | $18.24 | 2025 | Yesintek |
| Micro-Tech Endoscopy USA, INC. | $16.50 | 2022 | |
| Lucid Diagnostics INC. | $14.08 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Morris Naus listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.